Value in Health Special Issue: Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the U.S. and Other Countries
This special issue of Value in Health showcases presentations made at the Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the U.S. and Other Countries symposium held on May 15, 2009.
Articles in this issue include the following:
- Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries (pages S1–S3), Adrian R. Levy and Louis P. Garrison Jr.
- Health Technology Assessment in the United Kingdom (pages S4–S5), Ron Akehurst
- Health Technology Assessment and Comparative Effectiveness in Sweden (pages S6–S7), Egon Jonsson
- Conditionally Funded Field Evaluations: PATHs Coverage with Evidence Development Program for Ontario (pages S8–S11), Ron Goeree, Kiran Chandra, Jean-Eric Tarride, Daria O'Reilly, Feng Xie, James Bowen, Gord Blackhouse and Robert Hopkins
- Comparative Assessment for Medications and Devices: Apples and Oranges? (pages S12–S14), Scott Ramsey
- Contemporary Challenges in Deriving Summary Estimates of Comparative Effectiveness Using Meta-Analysis (pages S15–S17), Edward J. Mills
- Reflecting Heterogeneity in Patient Benefits: The Role of Subgroup Analysis with Comparative Effectiveness (pages S18–S21), Mark Sculpher
- Transportability of Comparative Effectiveness and Cost-Effectiveness between Countries (pages S22–S25), Andrew Briggs
- Experimental and Observational Data and Formulary Listing (pages S26–S29), Raulo S. Frear
- Net Clinical Benefit: The Art and Science of Jointly Estimating Benefits and Risks of Medical Treatment (pages S30–S32), Adrian Towse
Due to copyright issues, articles must be accessed through the Value in Health website. NPC has limited print copies available for order.
CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...
E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...
Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...CER Collaborative: Providing the Tools for Better Formulary Decisions
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...
NPC Survey Shows Health Care Stakeholders Continue to Show Optimism About Future Role of Comparative Effectiveness Research
(Washington, DC, March 19, 2013)—As the implementation of the Affordable Care Act (ACA) picks up speed, a new survey shows that health care...National Pharmaceutical Council Welcomes Amgen as Its Newest Member
Washington, D.C. (January 16, 2013)—The National Pharmaceutical Council (NPC) today welcomed biotechnology pioneer Amgen as its newest member. Joshua...National Pharmaceutical Council Comments on PCORI Approval of Research Methodology Standards
Washington, DC (November 19, 2012)—The National Pharmaceutical Council (NPC) today commented on the Patient-Centered Outcomes Research Institute’s (...New Fellowship in Policy Impact of Comparative Effectiveness Research Available Through a Partnership of the National Pharmaceutical Council and The George Washington University School of Public Health and Health Services
WASHINGTON, DC (October 23, 2012)–The National Pharmaceutical Council (NPC), in conjunction with The George Washington University School of Public...
The State of CER and the Environment for Health Care Decision Making
This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...Keeping Our Eye on the CER Ball
Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...Why Real-World Evidence Matters
National Pharmaceutical Council Director of Comparative Effectiveness Research Dr. Jennifer Graff explains the concept of real-world evidence (what...Challenges With Real-World Evidence
National Pharmaceutical Council Chief Science Officer Dr. Robert Dubois explains that how a drug might-or might not—work in a clinical trial could be...CER Collaborative: Assessing Evidence and Informing Decision-Making
National Pharmaceutical Council (NPC) Director of Comparative Effectiveness Research Dr. Jennifer Graff discusses an initiative designed to help...The State of Comparative Effectiveness Research and the Environment for Health Care Decision Making
NPC discusses the findings from its third annual survey that gauges the attitudes and expectations of comparative effectiveness research (CER) among...CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...CER Collaborative: Providing the Tools for Better Formulary Decisions
National Pharmaceutical Council Chief Science Officer Robert Dubois, MD, PhD, and Director of Comparative Effectiveness Research Jennifer Graff,...CER Tweets of the Week (Apr. 29 – May 3, 2013)
Conversations on Twitter about evidence and comparative effectiveness research highlighted the Agency for Healthcare Research and Quality’s call for...CER Tweets of the Week (Apr. 22-26, 2013)
A plan by the Patient-Centered Outcomes Research Institute (PCORI) to allocate $68 million to develop a network of research centers was widely...Research
Pharmaceutical Benefits Under State Medical Assistance Programs, 1973
This edition of the Pharmaceutical Benefits Under St
Principles for Planning and Conducting Comparative Effectiveness Research
A group of leading researchers developed a set of 13 best practice principles that could help to...
The Current Evidence-Based Medicine Landscape
This 2008 reference guide identifies and documents all relevant organizations, activities,...- 1 of 10
- >
Commentary & Testimony
The State of CER and the Environment for Health Care Decision Making
Keeping Our Eye on the CER Ball
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Living Up to Its Name? The Role of Patient-Centered Research
The Risks of Standardized Health Care